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Abstract
The prognosis of patients suffering from acute myocardial infarction (AMI) is 
related to the amount of muscle loss and ventricular function deterioration caused 
by the event. Primary angioplasty is the most effective reperfusion strategy. Early 
reperfusion limits the size of the infarction and improves the prognosis. However, 
the incidence of death and post-AMI heart failure remains around 20% during the 
first year. Factors that contribute to myocardial damage are ischemia, mechanical 
forces, inflammation, and reperfusion injury. All those take a variable and some-
times unpredictable preponderance at different times during the evolution of acute 
myocardial infarction. The damage caused by the different mechanisms is irrevers-
ible; therefore, any therapeutic strategy must be preventive. Developed treatments 
for continuous myocardial protection could potentially preserve the myocardium 
during the delay of the system and during the early evolution of the event. 
Developed controlled reperfusion procedures where the interventional cardiologist 
assumes the treatment not only of the culprit vessel but also of the myocardium 
could potentially decrease myocardial damage, preserve ventricular function, and 
improve patients’ prognosis.
Keywords: myocardial damage, acute myocardial infarction, ischemia, mechanical 
forces, inflammation, reperfusion injury, continuous myocardial protection, 
controlled reperfusion
1. Introduction
The prognosis of patients suffering from acute myocardial infarction (AMI) is 
directly related to the amount of muscle loss and the deterioration of ventricular 
function caused by the event [1–4]. Consequently, the goal of treatment in the ini-
tial phase, beyond preserving life, is to limit myocardial damage. Early reperfusion 
of the myocardium limits the size of the infarction and improves the prognosis of 
patients [3, 4]. Primary angioplasty is the most effective reperfusion strategy for the 
treatment of acute myocardial infarction [5–7]. From the first reports of mechanical 
reperfusion to the present, the primary angioplasty strategy continuously improved 
in different aspects such as greater accessibility to the method [8–10], safer vascular 
accesses [11, 12], and the use of drug-eluting stents that modulate the scarring 
of the coronary artery wall [13, 14] to prevent restenosis of the vessel or vessels 
treated. In addition, the development of antithrombotic and antiplatelet drugs also 
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contributed to improving early and late artery permeability [15, 16]. The enormous 
effort focused on the treatment of the coronary artery has led to the fact that the 
success of primary angioplasty is now greater than 95% [7]. The angiographic 
success rate ceased to be a problem. However, the post-AMI incidence of death 
and heart failure remains around 20% during the first year [17], and as mentioned 
earlier this correlates directly with the amount of myocardium damaged and the 
deterioration of ventricular function.
2.  The following case serves to illustrate the result of AMI usual 
treatment at present
52-year-old male, with grade II obesity, dyslipidemia, hypertension, and 
smoking history and with no previous cardiovascular events, arrives at the hospital 
60 minutes after the onset of symptoms. The first electrocardiogram (ECG) shows 
rS in V1, V2, and V3 and ST-segment elevation from V1 to V6 (Figure 1).
At admission the arterial blood pressure was 145/80 mm of hg, the heart rate was 
78 beats per minute, and the Killip Kimball grade was A. The patient received aspi-
rin (250 mg), clopidogrel (600 mg), unfractionated heparin in intravenous bolus 
(5000 UI), and rosuvastatin (40 mg). At 80 minutes after admission, 140 min-
utes from the onset of symptoms, coronary angiography is performed showing 
single-vessel disease with thrombotic occlusion of the middle third of the anterior 
descending artery (ADA) and TIMI 0 flow. Primary angioplasty is performed to the 
middle third of the ADA with thromboaspiration and stent implantation achieving 
an adequate result with TIMI 3 flow, symptom relief, and absence of complications. 
Figure 1. 
ECG at admission.
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The post-procedure ECG shows QS in V1, V2, and V3 and ST level and negative T 
from V1 to V6 (Figure 2).
IECA and B blockers are started. It evolves without recurrence of symptoms; 
however, at 48 hours, the ECG shows QS from V1 to V5 and low R in V6 (Figure 3).
Note that despite early assistance, it no longer has positive vectors in V1, V2, 
and V3, and after the usual successful treatment and aligned with the guidelines 
based on current evidence, it continues to lose precordial vectors after primary 
angioplasty. The echocardiogram shows antero-apical dyskinesia and impaired 
ventricular function, with an ejection fraction of 35% measured by the Simpson 
method. There are several mechanisms by which the myocardium is lost in the 
different phases of AMI.
Figure 2. 
ECG postprimary angioplasty.
Figure 3. 
ECG at 48 hours.
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3. Etiopathogenesis of myocardial damage
The factors that contribute to myocardial damage are as follows:
Ischemia.
Mechanical forces.
Inflammation.
Reperfusion injury.
3.1 Ischemia
It implies the interruption of blood flow, the supply of O2 and nutrients. The 
myocyte stops producing ATP from the fatty acid oxidation and switches to another 
metabolic pathway that is suboptimal not only because it cannot maintain a balance 
between nutrient supply and demand and O2 but also because of the accumulation 
of metabolic wastes that this route produces, and that generates an environment 
harmful to the subsistence of the cells and the appropriate reperfusion, favoring the 
phenomenon of reperfusion injury [18]. The alternative route for ATP production 
during ischemia is anaerobic glycolysis; its potential to produce ATP is 20 times 
less than aerobic glucose metabolism and even less than the route commonly used 
by myocyte which is the aerobic metabolism of fatty acids. The glycogen reserve 
as a source of anaerobic ATP is depleted in 30–60 minutes and also generates lactic 
acidosis, high concentration of protons at tissue level, and excess of H2O. The 
mechanisms of myocardial damage due to ischemia involve low production of ATP 
that is insufficient not only for myocyte function but also to preserve its structure 
and to maintain hydroelectrolytic balance by the Na-K ATPase pump, which implies 
an increase in Na and intracellular H2O with tissue and cellular edema, vacuoliza-
tion, and cell burst [19, 20]. Inactivation of the Na-K ATPase pump leads to the 
activation of the Na-Ca exchange, resulting in increased intracellular calcium with 
hypercontraction of myocytes (contraction band necrosis) [21, 22]. The entry of Ca 
into the cell is one of the mechanisms by which the permeability of the transition 
pores of the mitochondria increases and their destruction occurs [23]. Myocardial 
ischemia can be either primary before applying reperfusion therapy or secondary, 
that is, after recanalizing the occlusion. As for primary ischemia, it can occur in a 
sustained or episodic manner. In some cases, episodic primary ischemia can gener-
ate a protective myocyte phenomenon known as ischemic preconditioning [24]. 
The mechanical factors that produce arterial occlusion and primary ischemia are 
plaque thrombus, and vasospasm. Secondary ischemia is always harmful and may 
be due to failed angioplasty, no reflow phenomenon, distal embolism, thrombotic 
reocclusion, post-reperfusion, vasospasm, etc. Consequently, myocardial ischemia 
occurs from the onset of AMI and may end with primary angioplasty, or persist 
(not reflow), or recur after it.
3.2 Mechanical forces
The ischemic myocardium stops contracting and is distended; this situation 
subjects it to exceptional mechanical forces of tension, traction, and stretching. In 
each systole, the nonischemic myocardium, which acts in a state of compensatory 
hypercontractility, pulls on the edges of the ischemic myocardium. In addition, 
in each systole, the healthy myocardium presses the blood against the ischemic 
myocardium causing distension and increased wall tension [25]. These forces of 
stretching and traction produce direct tissue damage [26] but also by increasing the 
tumor necrosis factor trigger mechanisms of apoptosis [27] dependent on caspases 
that produce cell death in early and late stages of AMI. The strongest evidence of the 
5Primary Angioplasty: From the Artery to the Myocardium
DOI: http://dx.doi.org/10.5772/intechopen.91832
damage that mechanical forces can produce is the rupture of the ventricular wall. 
As they are direct forces exerted on the ischemic myocardium, it is to be assumed 
that the damage is related to the magnitude and frequency of exposure; therefore, 
the higher the heart rate and inotropism, the greater the damage produced by this 
mechanism. This mechanism of myocardial damage begins immediately after the 
onset of ischemia and lasts beyond reperfusion.
3.3 Inflammation
The inflammatory response during the acute ischemic event plays a decisive role 
in the size of the infarction and the subsequent adverse left ventricle remodeling 
[28]. The onset of myocardial ischemia during AMI triggers a pro-inflammatory 
response whose initial objective is to eliminate damaged cells and tissue from the 
injured area. This initial pro-inflammatory phase contributes to myocyte death and 
tissue damage [29, 30]. This phase is followed by a repairing anti-inflammatory 
stage that leads to healing. Balance alterations and the transition between the 
pro-inflammatory phase and the anti-inflammatory phase can increase myocardial 
damage during the event and contribute to an adverse left ventricle remodeling 
after AMI [28]. In addition, the inflammatory response as an acute phase reactant 
is related to the location and size of AMI. Large and anterior infarct shoots a greater 
extent of acute phase reactants. The initial pro-inflammatory phase includes com-
plement cascade activation and reactive oxygen species (ROS) production [28]. The 
damage-associated molecular patterns (DAMPs) production that binds to receptors 
in membranes cell and cytosolic proteins (inflammasomes), in either, circulating or 
myocardium resident cells. Inflammasomes cause caspase activation (which initiate 
the pyroptosis phenomenon, [apoptosis, and inflammatory necrosis]) and release 
pro-inflammatory cytokine as such as IL-1 and IL-8 and chemokines that recruit 
pro-inflammatory cells (polymorphonuclear, monocytes, macrophages, T and B 
lymphocytes) [28]. In addition, the inflammasomes activated during AMI induce 
ATP loss from the injured cells to the extracellular space, K outflow, lysosomal 
destabilization, and ROS generation by the mitochondria [28]. The anti-inflamma-
tory phase begins with neutrophil and dendritic cell arrival; these cells secrete anti-
inflammatory cytokines such as IL-10 and tissue growth factors that begin damaged 
tissue repair [28]. Monocytes and macrophages induced by interferon change their 
phenotype towards anti-inflammatory expressions [28]. Dendritic cells secrete 
chemotactic substances for regulatory T lymphocytes (CD4, CD25, and FOXP3) and 
T helper lymphocytes; these lymphocyte subtypes also secrete anti-inflammatory 
and reparative substances such as IL-10 and tissue growth factor and also induce 
the expression of anti-inflammatory macrophage phenotypes [28]. Although it is 
not proven, it is speculated that they could also activate pre- and post-conditioning 
mechanisms [28]. This myocardial damage mechanism is triggered in early stages 
after the onset of ischemia and continues beyond reperfusion.
3.4 Reperfusion injury
Myocardial reperfusion can itself produce more damage and cell death; this pro-
cess defines the phenomenon of reperfusion injury [31–33] that could be prevented 
by applying additional therapies [34]. Reperfusion injury could be responsible for 
up to 50% of the final myocardial damage during acute myocardial infarction. The 
time elapsed since the onset of symptoms, diabetes, TIMI 0 flow in baseline angi-
ography, DA involvement, and presentation with heart failure is associated with 
a greater chance of presenting reperfusion injury [35]. Elevation of white blood 
cells, greater activation (platelet size and reactivity), high levels of thromboxane 
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A2 and ET1, hyperglycemia associated or not with diabetes, and C-reactive protein 
before reperfusion are predictors of this phenomenon [36–38]. It is possible that 
there is always some degree of reperfusion damage, but the patients with little time 
of evolution of the symptoms and those who presented previous angina seem less 
susceptible [39, 40]. There is a useful premise to estimate its magnitude; the greater 
and more intense the ischemia, the greater the reperfusion injury [35, 41–43]. In 
daily practice, the lack of resolution of the ST segment after achieving epicardial 
coronary flow is used as a marker of reperfusion failure. In patients who do not 
correct the ST, the mortality of AMI triples beyond achieving adequate epicardial 
flow [44, 45]. The most important events that occur during reperfusion and trigger 
mechanisms of injury are the steep increase in oxygen content in a medium with a 
low PH (tissue acidosis caused by ischemia). In this scenario, O2 binds to hydrogen 
protons generating reactive oxygen species that by themselves generate DNA, 
protein, and lipid damage to the membranes and consequently direct cell death 
[46, 47]. Besides, reactive oxygen species have pro-inflammatory effects mediated 
by cytokines that cause apoptosis and cellular necroptosis [48]. At the level of the 
mitochondria, ROS causes the opening of the transition pores of their membranes 
making them susceptible to irreversible damage [48]. At the endoplasmic reticulum 
level, the damage caused by ROS alters the dynamics of calcium, which in the 
context of reperfusion of an acidotic environment generates calcium entry into the 
sarcolemma, producing sustained hypercontraction that results in necrosis with 
contraction bands [47–49]. The calcium entry activates Ca-dependent proteases 
that degrade structural components of the cell [50]. The reperfusion injury affects 
not only the myocyte but also the microvasculature, where ROS not only produces 
direct damage to the endothelial cells causing increased permeability of the capil-
lary wall resulting in edema but also is chemotactic for neutrophils, activates 
complement, and triggers pro-thrombotic phenomena [48–51]. In brief, microvas-
cular occlusion occurs due to perivascular edema, cluster of neutrophils, and local 
thrombosis. Injury due to reperfusion occurs due to the arrival of saturated O2 blood 
to myocardial tissue that is vulnerable to metabolic changes and the local internal 
environment, which occurred during ischemia. Reperfusion injury is a rapid and 
irreversible phenomenon [52].
The phenomena of ischemia, damage due to mechanical forces, inflammation, 
and reperfusion injury take a variable and sometimes unpredictable preponderance 
at different times during the evolution of AMI (Figure 4).
Also, the damage caused by the different mechanisms is irreversible; there-
fore, any therapeutic strategy must be preventive that implies pathophysiological 
Figure 4. 
Myocardial damage mechanism, importance, and development over time.
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conditions that culminate in myocardial damage and act before the point of no 
return in the viability of the cell occurs.
4. Analysis of guidelines for AMI treatment
Both the AHA-ACC guidelines and the ESC guidelines for AMI treatment are 
strongly oriented to early and sustained reperfusion, which constitutes the most 
powerful resource for improving prognosis and saving lives during the event. The 
best way to show successful post-PCI or thrombolytic reperfusion is to verify the 
correction of the ST segment of the ECG performed after reperfusion therapy. 
Approximately 30% of patients receiving primary angioplasty in a timely manner 
do not correct ST elevation or initially correct it but continue to lose positive ECG 
vectors after apparently successful reperfusion. As we saw in the previous section, 
this happens because there is myocardial damage before, during, and after reperfu-
sion [53]. However, the analysis of the guidelines shows that measures to reduce 
myocardial damage beyond reperfusion are poorly developed. The related items 
found in the current guides are reproduced below.
4.1 AHA-ACC guides 2013
4.1.1 Nitroglycerin
It improves the conditions of pre- and post-load of the ventricle and could also 
improve collateral flow and reduce BP which would improve the imbalance between 
supply and demand of O2 in some patients. Based on the evidence provided by a 
meta-analysis that included 22 clinical trials and more than 80,000 patients, 3 or 
4 deaths could be avoided per 1000 treated patients, which implies a net benefit. 
Nitroglycerin is a class I indication with a level of evidence C for patients with 
ischemic pain, hypertension, or pulmonary congestion [54].
4.1.2 B blockers
During the first hours of AMI, the B blockers can decrease the demand for O2 
by the myocardium by decreasing heart rate, blood pressure, and contractility and, 
additionally, by prolonging diastole, can improve ischemic myocardial perfusion, 
mainly of the subendocardium. As a consequence of this, B blockers can reduce the 
size of the AMI. Based on the clinical evidence provided by the ISIS I, MIAMI, TIMI 
II, and Taste I trials, the use of B blockers early, in the absence of contraindica-
tions, may offer benefits from the first day and in a sustained way avoiding around 
6 deaths per 1000 patients treated. B oral blockers have class I indication level of 
evidence A, and in the form of intravenous administration, they have class IIa 
indication with level of evidence B [55–57].
4.1.3 Metabolic control
The metabolic modulation of the insulin glucose axis by infusion of glucose-
insulin-potassium was evaluated in different trials with diverse and contradictory 
results that when taken together result in an intervention without net benefit 
compared to placebo. However, these guidelines suggest that it could be of benefit 
in patients with less than 12 hours of evolution, in Killip Kimball. Beyond that, the 
guidelines do not establish an indication with a level of evidence defined for this 
intervention [58].
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4.1.4 Glycemia control
During AMI, the levels of catecholamines and cortisol increase, insulin 
decreases, and blood glucagon increase. This leads to a notable increase in blood 
glucose and decreased glucose utilization by cells. Free fatty acids and their metabo-
lites are increased that increase myocardial damage by different mechanisms (direct 
inhibition of glucose oxidation, increased demand for O2, direct toxicity). Insulin 
can reverse some of these mechanisms by inducing the production of ATP from 
aerobic glucose metabolism in the myocyte. Several studies mentioned in these 
guidelines demonstrated benefits in patients with hyperglycemia who received 
insulin infusion for strict glycemic control during the event. These guidelines estab-
lish that the normalization of insulin glycemia is a class I indication with a level of 
evidence B for patients with complicated AMI and class IIa with a level of evidence 
B for patients with uncomplicated AMI [59–61, 62].
4.2 ESC guides 2017
These guidelines mention, scarcely, that to reduce myocardial damage beyond 
reperfusion therapy, some strategies that include pharmacological and mechanical 
therapies have been demonstrating the potential to reduce the size of AMI by decreas-
ing the impact of reperfusion injury in small clinical trials. But there is no large-scale 
clinical study that has demonstrated clinical benefit. Therefore, they make no recom-
mendation regarding measures to limit reperfusion injury or any other therapy to 
reduce myocardial damage during the event, beyond reperfusion [63].
5. Current reperfusion adjuvant therapy status
The use of B blockers and nitrates is favorable to reduce myocardial damage 
caused by primary and secondary ischemia, reducing the imbalance between supply 
and demand of O2 and nutrients until reperfusion. Beside, these drugs are useful 
to optimize the conditions of pre- and post-loading of LV, decrease heart rate and 
blood pressure, and thus limit the damage caused by mechanical stress. A wide 
variety of potent platelet antiplatelets such as clopidogrel, prasugrel, or ticagrelor 
added to the routine use of aspirin were shown to reduce the recurrence of ischemic 
events after reperfusion (secondary ischemia). Although it is not clearly established 
by evidence from clinical trials, thromboaspiration; potent vasodilators at the 
microvasculature level such as adenosine and calcium blockers, among others; and 
the use of IIb–IIIa glycoprotein inhibitors may be effective in prevention and treat-
ment of no-reflow. The phenomenon of no-reflow can cause ischemia (secondary 
ischemia) to continue beyond the recanalization of the epicardial artery. However, 
reperfusion inflammation and injury are not prevented or treated in daily practice.
6. Perspectives
The development of reperfusion therapies for AMI was shown to reduce mortal-
ity strongly. There are possibilities to optimize its use. Health teams must continue 
fighting to shorten the system times and detect the best strategy according to the 
context in which they operate. There are working groups that carry out research in 
basic sciences, translational research, and clinical research and are making advances 
in myocardial protection. Cyclosporine and colchicine are currently evaluated for 
their ability to reduce the damage caused by inflammation. Developed treatments 
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for continuing myocardial protection [52], which the clinical cardiologists administer 
from the moment of diagnosis until the convalescence of the patient in a critical 
unit, could potentially preserve myocardium during the delay of the system and 
the early evolution of the event. Developed controlled reperfusion [52] procedures 
where the interventional cardiologist assumes the treatment not only of the guilty 
vessel but also of the myocardium could potentially decrease myocardial damage, 
preserve ventricular function, and improve the prognosis of patients suffering from 
AMI. The concept of controlled reperfusion involves deciding how to reperfuse (e.g., 
post-conditioning) and with what to reperfuse (e.g., administering to the ischemic 
myocardium, through dedicated catheters, before the opening of the artery, blood 
modified or enriched with drugs), preparing the myocardium for a more complete 
and definitive recovery.
A wide field of research appears to improve the treatment outcome of patients 
suffering from AMI aiming not only at arterial recanalization but also at myocardial 
preservation.
Abbreviations
AMI acute myocardial infarction
ECG electrocardiogram
ROS reactive oxygen species
ADA anterior descending artery
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